Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Thornhill Therapeutics Inc. currently has 2 pending office actions, 2 distinct examiners, and 2 distinct art units within the Biotechnology & Pharmaceuticals technology area. This results in an allocation of 1 case for each official. The prosecution being divided across these 2 distinct art units implies that the underlying technology is being evaluated by different specialized groups within the biotechnology sector. This requires the applicant to address the specific requirements of two different examination teams.
The busiest examiner identified in the data is ZEMAN, ROBERT A, who is responsible for 1 pending action. This constitutes a portion of the company's current active workload at the patent office. Since there are 2 distinct examiners and 2 distinct art units involved, the company does not face a concentration of its 2 pending office actions in any single administrative or technical silo. This spread allows the applicant to diversify the prosecution risk across multiple reviewers. Practitioners should prepare for distinct procedural styles from each assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931558 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18931558 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | ZEMAN, ROBERT A | — |
| 18926142 | TOXIN-DERIVED DELIVERY CONSTRUCTS | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18931558 | CHOLIX TOXIN-DERIVED FUSION MOLECULES FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE CARGO | ZEMAN, ROBERT A | 1645 | §102§103Other | Non-Final OA | — | Pending | Oct 30, 2024 |
| 18926142 | TOXIN-DERIVED DELIVERY CONSTRUCTS | TSAY, MARSHA M | 1656 | §103DP | Non-Final OA | — | Pending | Oct 24, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThornhill Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert A Zeman has the most, with 1 of Thornhill Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
